Amgen Announces Transition Plans for Two Executive Officers

By Akia Thorpe -

July 31, 2018

Amgen has announced transition plans for two of its executive vice presidents (EVPs), Sean E. Harper, MD, EVP of Research and Development (R&D) and Anthony C. Hooper, currently EVP of Global Commercial Operations.

After 16 years with Amgen, Harper, has decided to retire and plans to pursue opportunities in the early-stage biotechnology community.

David M. Reese, MD, currently Senior Vice President of Translational Sciences and Oncology at Amgen, has been appointed as EVP of R&D. Since joining Amgen in 2005, Reese has served in a variety of leadership roles, including in development, medical sciences, as Head of Discovery Research, and in translational sciences, where he had responsibility for introducing all of Amgen's early medicines into clinical development. Reese will report to Robert A. Bradway, Chairman and Chief Executive Officer. Harper will remain at Amgen for a period of time to facilitate the transition to Reese.

In September 2018, Anthony C. Hooper, EVP of Global Commercial Operations, will retire from this role. Murdo Gordon, formerly Chief Commercial Officer of Bristol-Myers Squibb (BMS), has been named as EVP of Global Commercial Operations, effective September 3, 2018.

Gordon announced his departure from BMS in July (2018). In his role at BMS, Gordon was responsible for commercial strategy across the globe, including all sales and marketing activities as well as customer operations, access and pricing. Prior to this, Gordon served as head of worldwide markets with responsibility for promoting all the company's brands globally. Gordon will report to Bradway. Hooper will also remain at Amgen for a period of time to facilitate the transition to Gordon.